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Summary The circulating cytokine concentrations following administration of subcutaneous recombinant interleukin 2 (IL-2) in combination
with interferon a and 5-fluorouracil used to treat advanced renal cancer were studied. One patient was anephric and on dialysis, and seven
had normal biochemical renal function, although five had undergone single nephrectomy. The pharmacokinetics of IL-2 and changes in IL-6
and tumour necrosis factor (TNF)-a were essentially similar in all patients including the anephric patient, irrespective ofthe periods ofdialysis,
although at some time points, IL-2 concentrations were slightly higher in the anephric patient than in the others. These results show that for
subcutaneous administration of low-dose IL-2, renal clearance of IL-2 is not important. This contrasts with high-dose, intravenous IL-2 where
blood concentrations are higher and renal clearance seems to occur, perhaps because of saturation of the non-renal mechanisms of
clearance. The subcutaneous route is certainly preferred if IL-2 is used in anephric patients and in those with impaired renal function, and it
may be generally preferred for most purposes.
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The use of interleukin 2 (IL-2) as a biological anti-cancer therapy
is based on its ability to activate and enhance the cytotoxic activity
of T lymphocytes and to stimulate natural killer cell- and
lymphokine-activated killer cell activity. These actions are prob-
ably mediated both directly and via secondary induction of a
cascade of cytokines including tumour necrosis factor (TNF)-a
and IL-6 (Whittington and Faulds 1993; Janssen et al, 1994).
Multiple regimens with IL-2 have been developed, but progress
has been hampered by the marked toxicity associated with many
of the higher dose intravenous (i.v.) regimens employed, most
notably a capillary leak syndrome (similar to that seen in patients
with septic shock) manifest by hypotension, weight gain, acute
renal failure and pulmonary oedema (Whittington and Faulds,
1993). Newerapproaches using lowerdose subcutaneous (s.c.) IL-
2 have beenpromising with, forexample, recent combinationregi-
mens producing objective responses with less accompanying
toxicity in 30-40% ofpatients with metastatic renal cellcarcinoma
(Atzpodien et al, 1990; Atzpodien-et al, 1993; Joffe et al, 1996).
An understanding of cytokine metabolism is important for
ensuring arational approach to thedesign oftherapeutic strategies,
particularly with regard to route ofadministration and dosage. The
mechanism ofclearance is an important consideration as IL-2, for
example, may be administered to patients who have undergone a
nephrectomy, occasionally bilateral nephrectomies, and IL-2 itself
may cause renal dysfunction. The pharmacokinetics of IL-2
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following i.v. administration is generally thought to be consistent
with a two-compartment model with first-order elimination
kinetics. In rodents, an initial rapid clearance with a half-life (t,2)
ofapproximately 1-5 min is followed by a more prolonged elimi-
nation phase with a t1/2, depending on the study, of 9-40 min
(Donohue and Rosenberg, 1983; Chang et al, 1984; Donohue et al,
1984; Koths and Halenbeck. 1985; Gibbons et al, 1995). Similar
results have been found in humans with an initialt,12 of6-13 min
followed by a second phase with a t1/2 in excess of 1 h and 95%
of circulating IL-2 being cleared within 30 min (Lotze et al,
1985; Konrad et al, 1990). The calculated plasma clearance of
120 ml min-m is consistent with renal clearance (Lotze et al, 1985).
This is supported by animal studies showing a rapid renal accumu-
lation of radiolabelled IL-2 (Koths and Halenbeck, 1985; Ohnishi
et al, 1989) and marked prolongation of the half-life by double
nephrectomy or ligation of the ureters or renal pedicles (Donohue
and Rosenberg 1983; Gibbons et al, 1995). If the hydrodynamic
size of IL-2 is comparable to that predicted by its covalent struc-
ture, glomerular filtration would be expected to occur. Although
intact IL-2 has not been detected in urine following i.v. administra-
tion, fragments ofIL-2havebeenfound. These arethoughtto occur
as a result of catabolism by renal cathepsin D with the specific
inhibitor pepstatin decreasing the renal accumulation of IL-2 and
increasing thet,/2 (Ohnishi et al, 1989; Ohnishi et al, 1990).
Most studies examining IL-2 clearance have been concerned
with i.v. administration in which relatively high circulating IL-2
concentrations are achieved. Subcutaneous administration is
increasingly being usedclinically. Limitedpharmacokinetic studies
have shown that s.c. administration results in steady-state circu-
lating IL-2 concentrations for approximately 8 h with levels being
50- to 100-fold less than those found following i.v. administration
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Figure 1 Plasma IL-2 concentrations as measured by immunoassay in (A) seven patients with normal renal function and (B) the anephric patient, following
subcutaneous IL-2 injections as described in Materials and methods. The times of injections are indicated by the vertical arrows (T) and the periods of dialysis
for the anephric patient are indicated by horizontal arrows (<-*). Standard deviations are not shown but were usually < 5%
depending on the dose used (Konrad et al, 1990), but it is not
known whether the same mechanisms of clearance apply. In
support of an alternative clearance mechanism at lower doses are
the briefreports ofthe treatment ofthree anephric patients with s.c.
IL-2, two ofwhom experienced similar toxicity to that experienced
by many patients with normal renal function apart from more
pronounced hypotension (Buter et al, 1992) and the other experi-
encing more severe toxicity (OMS . grade 3), necessitating a dose
reduction from 18 to 9 x 106 Units of IL-2 (Suc et al, 1995). We
have explored this further by comparing directly the cytokine
profiles during subcutaneous IL-2 therapy of eight patients with
normal renal function and one anephric patient on haemodialysis
who had previously undergone bilateral nephrectomy.
MATERIALS AND METHODS
Patients
Eight patients (three female, five male, age range 34-67 years)
who were taking part in a phase II study of interferon a (IFN-a),
IL-2 and 5-fluorouracil (5-FU) in advanced renal cell carcinoma
were studied. The clinical findings of the trial have previously
beenreported in detail (Joffe etal, 1996). Sevenpatients hadhisto-
logically proven metastatic renal cell carcinoma and one had a
Bellini duct tumour. Seven patients, five of whom had undergone
prior unilateral nephrectomy, had normal biochemical and haema-
tological indices (with the exception ofthose affected by the renal
cancer), with no significantdegree ofrenal impairment as assessed
by serum creatinine and urea levels, and were of performance
status 0-2 (ECOG). The eighth patient had undergone bilateral
nephrectomy and had been maintained on haemodialysis thrice
weekly for five months before commencing IL-2 therapy for
recurrent metastatic disease.
Treatment
Patients were treated with a combination ofIFN-a, IL-2 and 5-FU
in an 8-week schedule as described previously (Atzpodien et al,
1993). During the first week of therapy when the blood samples
for this study were taken, recombinant human IFN-a-2a (Roferon,
Roche) was administered by subcutaneous injection (6 MIU m-2)
at 16.00 h on day 1 (Monday) and non-glycosylated recombinant
human IL-2 (Proleukin 18 MIU mg-', Eurocetus/Chiron) was
given by s.c. injection (10 MIU m-2) twice daily at 09.00 and
18.00 h on days 3-5.
Patient samples
Venous blood samples were taken from the patients during the first
week oftherapy. Sampling times were before the start of the trial,
immediately before the first IL-2 injection (t = 0), and at 4, 8, 12,
24 (immediately before the third IL-2 injection), 48 (immediately
before the fifth IL-2 injection), 52, 56, 60 and 120 h following the
first IL-2 injection. At each time, the sample was divided into
three tubes containing the anticoagulants EDTA, citrate and no
anticoagulant. Within 15 min of collection, samples were
centrifuged at 1500 g for 10 min, the plasma and serum aliquoted
and stored at -70°C until assayed. Urine samples were also
obtained from two additional patients during the first 9 h of IL-2
therapy, centrifuged at 1500 g for 10 min to remove cells and
stored at -70°C until assayed. Inforned consent was obtained
from patients in accordance with the local research ethics
committee guidelines.
C-reactive protein (CRP) assay
CRP was measured in serum samples by standard nephelometric
procedures using a Behringwerke Nephelometric Analyser 100
(Behringwerke, Germany), with antibodies obtained from Atlantic
Antibodies and calibrant from the Protein Reference Unit
(Sheffield, UK).
Cytokine immunoassays
IL-2, IL-6 and TNF-a were measured in duplicate in plasma
samples using commercially available immunoassays (EASIAs,
Medgenix Diagnostics, Belgium) according to manufacturer's
instructions. Minimum detection limits were 0.1 IUJ ml-', 2 pg mi-l
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Figure 2 Plasma IL-2 concentrations as measured by bioassay and immunoassay for (A) one patient with normal renal function and (B) the anephric patient,
following subcutaneous IL-2 injections as described in Materials and methods. The times of injections are indicated by the vertical arrows (T) and the periods of
dialysis for the anephric patient are indicated by horizontal arrows (*e). Standard deviations are not shown but were usually <5% *- -, Immunoassay; 0- -0,
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Figure 3 Plasma IL-6 concentrations as measured by immunoassay in (A) seven patients with normal renal function and (B) the anephric patient, following
subcutaneous IL-2 injections as described in Materials and methods. The times of injections are indicated by the vertical arrows (T) and the periods of dialysis
for the anephric patient are indicated by horizontal arrows (+->). Standard deviations are not shown but were usually < 5%
and 3 pg ml-' respectively. Suitability for use with these samples Cytokine bioassays
was tested by performing a preliminary evaluation on several
samples, which examined recovery of spiked cytokine and paral-
lelity of diluted samples with the standard. Assays were standard-
ized against the first International standard for IL-2 (86/504), IL-6
(88/514) and TNF-a (87/650). An aliquot of 1 IU ofEurocetus IL-
2 (as determined by the manufacturer's bioassay) is equivalent to
0.38 IU detected using the immunoassay. This discrepancy is due to
structural differences between International standard IL-2 and
Cetus IL-2 when measured immunologically. Soluble IL-2 receptor
levels were measured using acommercially available immunoassay
(Cellfree IL-2R kit, T Cell Diagnostics, Cambridge, MA, USA).
The limit ofdetection was approximately 24 U ml-'.
IL-2 was measured in citrated plasma samples using a bioassay
based on the IL-2-dependent mouse cytotoxic lymphocyte cell
line, CTLL-2 (Gillis et al, 1978; Wadhwa et al, 1995). For this,
50 g1 of cell suspension (5 x 103 cells) was added to 50 ,l of
test samples or control medium and cultured for 18 h in 96-
well microtitre plates. A titration of an IL-2 working standard
calibrated directly against the World Health Organization 1st Inter-
national standard for human IL-2 (86/504) was included in each
assay. The cultures were then pulsed for 4 h with [3H]-thymidine
(0.5 ,Ci per well), harvested onto filter mats, and the radioactivity
incorporated into DNA estimated by scintillation counting. The
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Figure 4 TNF-a concentrations as measured by immunoassay in (A) seven patients with normal renal function and (B) the anephric patient, following
subcutaneous IL-2 injections as described in Materials and methods. The times of injections are indicated by the vertical arrows (T) and the periods of dialysis
for the anephric patient are indicated by horizontal arrows (-). Standard deviations are not shown but were usually < 5%
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Figure 5 CRP concentrations in (A) seven patients with normal renal function and (B) the anephric patient, following subcutaneous IL-2 injections as described
in Materials and methods. The times of injections are indicated by the vertical arrows (T) and the periods of dialysis for the anephric patient are indicated by
horizontal arrows (<->)
concentration ofIL-2 in the samples was calculated using parallel-
line analysis (Wadhwa et al, 1995).
TNF-a was measured in citrated plasma samples by a cytotoxi-
city assay using the murine WEHI 164 clone 13/2F2 (Meager et al,
1989). A titration of a TNF-a working standard calibrated directly
against the World Health Organization 1st International standard
for human TNF-cx (87/650) was included in each assay. Incubation
of serially diluted samples and standard with cells (2 x 104 per
well) was carried out at 37°C for 72 h. Cell survival was esti-
mated with 3-(4-5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium
bromide (MTT; 10 ul per well of 5 mg MTT ml-l PBS). The
formozan product of MTT formed in metabolically active cells
was eluted with 10% (w/v) sodium dodecyl sulphate (SDS) in
0.02 M HC1 (25 ul per well) after 1 h at 37°C. Optical densities
were read at 590 nm and cell survival, as a percentage, calculated
for each TNF-ax concentration, by the formula:
Per centcell OD590 TNF treated cells -OD590 background x 100
survival = OD590
untreated cells OD590 background
The assay end point, arbitrarily defined as 50% cell survival,
was equivalent to 0.2 IU ml-'.
Statistical analysis
Statistical analyses were carried out using the statistical package
SPSS-PC. The z-test was used for analysis ofthe difference in IL-
2 profiles and the correlation between bioassay and immunoassay
data was assessed by Spearman's rank correlation.
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Figure 6 Circulating soluble IL-2 receptor concentrations in six patients with
normal renal function following subcutaneous IL-2 injections as described in
Materials and methods. The times of injections are indicated by the vertical
arrows (1'). Standard deviations are not shown but were usually < 5%
RESULTS
The treatment response and toxicity data for these patients has
already been reported in detail as part of a larger study (Joffe et al,
1996). The anephric patient experienced no more appreciable toxi-
city than the other patients studied, with grade 2 toxicity in terms of
fatigue, pyrexia, dry skin, flushes, anorexia, vomiting andheadache.
The IL-2 profiles for all the patients in the first week ofthe trial
are shown in Figure 1 with the individual profiles shown to illus-
trate the interindividual variation. Seven patients received 18 x 106
IU ofIL-2 and one patient (Figure 1, 0- - -0), received 15 x 106 IU.
Because of the limited number of sampling points in this study, a
detailed pharmacokinetic analysis of the results is not possible.
However, it is clear that the profile of changes in the anephric
patient following IL-2 injections is similar to that found for
patients with normal renal function, irrespective of the periods of
dialysis. The circulating concentration of IL-2 in the anephric
patient was significantly higher (P < 0.05) at 4, 8 and 24 h (P <
0.001, z-test) than the corresponding means for the six patients
with normal renal function who received the same doses of IL-2
but showed no significant difference at any other time points.
Biologically active IL-2 was detected in all plasma samples from
all three patients examined and showed a good correlation (P <
0.001) with the immunologically detectable IL-2 as demonstrated
for one patient with normal renal function and the anephric patient
(Figure 2). In the two patients with normal renal function whose
urine was collected, approximately 200 IU of IL-2 was present in
each of the 9-h urine collections when assayed by immunoassay,
but no IL-2 was detected by bioassay.
The changes in circulating IL-6 and TNF-a concentrations are
shown in Figures 3 and 4 respectively, with the majority ofpatients
having elevated concentrations ofthese cytokines before treatment
(normal ranges of > 8.5 pg ml-' and 20 pg ml-' respectively
according to the manufacturer's findings and confirmed by
ourselves in a limited number ofhealthy volunteers). As with IL-2,
the profiles are very similarbetween the anephric patient and other
patients irrespective of dialysis, with an increase in IL-6 being
seen within 4 h ofthe first IL-2 injection. The pretreatment level of
TNF-ax was significantly higher in the anephric patient and addi-
tionally pretreatment dialysis resulted in an elevation in TNF-a
levels. Unlike the cytokines IL-2 and IL-6, TNF-a concentrations
tended to continue increasing throughout the 3-day period of IL-2
injections, falling towards baseline levels only following cessation
ofIL-2 therapy. Biologically active TNF-a was detectable in only
one blood sample (10 IU ml-') of all the samples examined from
five patients, namely that taken from the anephric patient 4 h after
the first IL-2 injection. Of the two urine samples examined, one
contained a total of500 pg ofTNF-a and 3600 pg ofIL-6, but no
biologically active TNF-a was present (< 1 IU ml-1).
Pretreatment CRP levels were lower in the anephric patient than
in six of the seven other patients, the exception being the only
patient with normal CRP levels (< 10 mg 1-1; Figure 5). A marked
increase in CRP occurred with IL-2 treatment, although this was
less marked or almost absent in those patients with the most
severely elevated CRP concentrations pretreatment (>100 mg 1-1).
In the anephric patient and the patient with normal CRP levels
pretreatment, the onsetofthe increase appeared tobe delayed until
24-48 h following the start QfIL-2 treatment. CRP concentrations
remained elevated even 60 h after cessation of IL-2 injections. In
several of the patients, there appeared to be an initial decrease in
CRP concentrations following the first IL-2 injection each day.
Pretreatment concentrations ofcirculating soluble IL-2 receptor
were abnormal in the majority of the six patients examined
(normal range < 860 U ml-'; 95th percentile, n =44 healthy volun-
teers, age 22-69 years), increasing within 12-24 h ofthe first IL-2
injection (Figure 6) in all patients. This increase was maintained
throughout the period ofIL-2 therapy examined and for at least the
following 60 h, with considerable interindividual variation in the
levels achieved.
DISCUSSION
The qualitative similarity in the concentration-time profiles ofthe
cytokines IL-2, IL-6 and TNF-a during s.c. IL-2 therapy between
patients with normal renal function and an anephric patient, irre-
spective ofthe periods ofdialysis, clearly demonstrates that mech-
anisms of clearance other than renal filtration exist for these
cytokines. The similarity of the cytokine profiles, although slight
quantitative differences exist, in patients with normal renal func-
tion to those of the anephric patient, together with the limited
amount ofcytokines detected in urine, suggests that a similar non-
renal clearance of cytokines is also operating in the patients with
normal renal function and that the non-renal clearance is not an
adaptive response in the anephric patient. It is possible that the
cytokines detected in urine may be proteolytic fragments as found
in mice following i.v. IL-2 (Ohnishi et al, 1989, 1990), and it is
possible that much larger amounts of proteolytically degraded
cytokines are present but not detected by the assays used.
There is evidence from animal studies of predominantly renal
clearance of several cytokines such as IL-10 (Chiu et al, 1996),
TNF-a (Ferraiolo et al, 1989; Kudo et al, 1990) and IFN-a (Bino
et al, 1982; Bocci et al, 1982). Evidence from animal and human
studies clearly demonstrates a renal clearance of IL-2 following
i.v. administration (Donohue and Rosenberg, 1983; Donohue et al,
1984; Lotze et al, 1985; Ohnishi et al, 1989, 1990; Konrad et al,
1990; Gibbons et al, 1995; Nadeau et al, 1995), with a very rapid
initial clearance followed by a more delayed clearance thought to
be due to the slower release from the extravascular space back to
the plasma. In rats, double nephrectomy produces an approximate
twofold increase in the half-life of IL-2, a 10- to 20-fold increase
in initial plasma levels and a 75% reduction in the clearance of
IL-2 (Gibbons et al, 1995), which supports the existence of an
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additional but less efficient clearance mechanism. The reason for
the apparent discrepancy of our study with the reported mecha-
nisms ofcytokine clearance is probably due to the dosing regimen.
Subcutaneous administration results in circulating IL-2 levels
approximately 2% ofthose following i.v. bolus injection and 20%
of those following i.v. infusion (Konrad et al, 1990). If much of
this circulating IL-2 was gradually bound to otherproteins such as
the soluble receptor, immunoglobulins ora2-macroglobulin, as has
been described for other cytokines such as IL-6 (Matsuda et al,
1989; May et al, 1992, 1994), the renal clearance is likely to be a
small component as the bound IL-2 would not be filtered by the
kidney owing to its size, but rather removed by the liver, orbound
to the IL-2 receptor and endocytosed. This may not be the case,
however, athigherdoses ofIL-2 thatinduce vascular leak and may
thus allow filtration of bound forms of IL-2. In animal studies,
non-linear components ofIL-2 elimination were apparent at lower
concentrations of IL-2, although not explored further (Gibbons et
al, 1995). Complexed forms of IL-2 have been found in mice
following i.v. IL-2 (Koths and Halenbeck, 1985) with a slower
clearance than free IL-2 and with the ratio ofthe complexed forms
to the free form decreasing with increasing dose of IL-2,
suggesting that a saturable process may be in operation predomi-
nantly at lower IL-2 concentrations. The significantly higher IL-2
concentrations in the anephric patient atfourtimepoints compared
with the mean of the patients with normal renal function suggests
that the area under the concentration-time curves for these inter-
vals may be slightly greater in the anephric subject, implying
either a reduced clearance and/or increased fraction of dose
absorbed in this patient. However, the difference is small and, as
can be seen from the profiles overlaps with the patients with
normal renal function, again implying that renal clearance if
present normally accounts for only a small proportion of total
clearance in this regimen and may only be important at early time
points before possible IL-2 binding mechanisms are initiated. It is
important to observe that the datapresented in this study are based
on interferon-primed individuals, unlike the studies discussed
above, but this is unlikely to have affected the potential for renal
clearance of IL-2 as no apparent effect on renal function was
observed.
At higher IL-2 levels, saturation of such binding processes may
be expected to occur and lead to the renal filtration anddegradation
offree IL-2 described at higher IL-2 concentrations. The excellent
correlation between the IL-2 levels measured by bioassay and
immunoassay indicates that the form of IL-2 measured by the
immunoassay reflects or is in equilibrium with that which is
biologically active. The IL-6 and TNF assays measure both free
and receptor-bound cytokine and the absence ofbioactive TNF-a
in the majority of samples indicates that the TNF present is likely
to be complexed to the soluble receptor, whichincreases during IL-
2 therapy (Lindemann et al, 1994), or possibly other proteins and
therefore is unlikely to be cleared by renal filtration to any great
extent. Similar changes in TNF-a have been reported previously
with low-dose IL-2 therapy, with the magnitude of the change
being related to the clinical response (Meffert et al, 1995).
In patients with renal disease, concentrations of cytokines such
as IL-1, IL-6 and TNF-a, and soluble TNF receptors are known to
be increased relative to those with normal renal function. The
process of dialysis is also known to cause increases in some
cytokines such as TNF-a although changes induced by dialysis
vary with the type of membranes used (Cavaillon et al, 1992;
Jorres et al, 1992; Nakahama et al, 1992; Ward and Gordon, 1993;
Canivet et al, 1994; Halwachs et al, 1994; Leeuwenberg et al,
1994; Pereira et al, 1994). This probably accounts for the higher
TNF-a concentrations seen in the anephric patient before treat-
ment with IL-2. Elevations ofIL-6 inpatients withrenal cell carci-
noma have also been demonstrated previously, correlating with
prognosis (Blay et al, 1992) or survival (Stadler et al, 1992). The
degree to which IL-6 or CRP are elevated before IL-2 treatment
has been studied in patients with renal cell carcinoma, melanoma
and gastrointestinal malignancies and shown to be inversely
related to response, with the magnitude ofthe changes seen during
treatment being related to response to therapy (Broom et al, 1992;
Blay et al, 1994; Deehan et al, 1994; Tartour et al, 1994). The
changes in CRP probably occur as a result ofchanges in either IL-
6 or TNF-a, both of which are known to induce the acute-phase
response. The reasons for the apparent consumption of CRP,
which have not been reported previously, are not clear. However,
CRP is known to formcomplexes (eithercalcium-dependent orvia
polycation binding sites) with many ligands, including nucleic
acids and choline phosphatides, subsequently participating in
several inflammatory reactions including the activation ofcomple-
ment (Pepys, 1981), which is known to occur during IL-2 therapy.
The changes in soluble IL-2 receptors are similar to those reported
in other studies (Lindemann et al, 1994; Gooding et al, 1995) and
may account for the inhibition ofIL-2 in vivo orbe involved in its
clearance. Thedetection ofsome IL-2 bioactivity probably reflects
a fraction of IL-2 in equilibrium with its soluble receptor from
which it readily dissociates. Evidence also suggests that other
inhibitors of IL-2 bioactivity may be induced during IL-2 therapy
(Gooding et al, 1995), although their identitiy is as yet unknown.
This demonstation ofnon-renal clearance mechanisms for some
cytokines has implications for cytokine therapy. For example low
dose IL-2 in an anephric patient on haemodialysis should be asso-
ciated with no appreciable greater toxicity than that experienced
by patients with normal renal function. Intravenous IL-2 however
is likely to be much more toxic in anephric patients. The similar
clearance of cytokines irrespective of the periods of dialysis may
indicate that normal renal function is not necessarily a criteria for
selection ofpatients for low-dose s.c. IL-2 therapy. However, this
needs further investigation as some mediators of toxicity may be
subject to renal clearance, although not apparent here due to the
regular dialysis periods.
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